Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

This was the stock's fourth consecutive day of gains.

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.